Interim Phase 2 Survival Data for PV-10 Will Be Presented by Professor John F. Thompson, MD, on November 21, 2009
Lead Investigator for Provectus' PV-10 Trial Will Present At 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers in Berlin
Will Update Compassionate Use Program
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Nov 17, 2009 - Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany.
In his presentation entitled “PV-10 in the Local Treatment of Melanoma Metastasis,” Professor Thompson will be presenting overall survival data for the Phase 1 and Phase 2 trials as well as an update on data from the expanded access use of PV-10 in Australia and the United States (“Compassionate Use”). Provectus expects to issue a press release to update shareholders and the medical and scientific community regarding the data early next week after the completion of the presentation.
Craig Dees, PhD, CEO of Provectus said, “We are excited about Professor Thompson's presentation, which will be the first time that interim survival data for the Phase 2 trial will be presented. Further, his discussion will provide the first look at the progress that has been made with our expanded access program for PV-10, the means through which certain qualified patients can receive PV-10 on a compassionate use basis, in Australia and the United States. Both of these aspects of his presentation are certain to be very enlightening on the topic of PV-10's continued development.”
About the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancers
This meeting provides a unique opportunity for melanoma clinicians and researchers, who are part of multidisciplinary melanoma/skin cancer centers to interact, learn from one another, establish collaborations and set an agenda for the further evolution of multidisciplinary melanoma care and research. The conference will feature Plenary Session and Symposia speakers who are recognized experts in melanoma treatment and research.
PV-10 is a proprietary, injectable formulation of Rose Bengal, a compound that has been in use for nearly thirty years by ophthalmologists to assess damage to the eye. It has also been used as an intravenous diagnostic to detect ailments of the liver. Rose Bengal is a small molecule agent with an established safety history, a short half-life in the bloodstream, and is excreted via the liver and kidneys. Provectus has discovered a novel use for Rose Bengal based on the observation that it is selectively toxic to cancer calls via a process called chemoablation whereby cells undergo a form of cell death that mimics both features of necrosis and apoptosis.
About Provectus Pharmaceuticals, Inc. (www.pvct.com)
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its lead oncology agent, PV-10, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic liver cancer. The Company has received orphan drug designation from the FDA for its melanoma indication. Its lead dermatological drug, PH-10, also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed enrollment in three of its Phase 2 trials -- PV-10 as a therapy for metastatic melanoma, and PH-10 as a topical treatment for atopic dermatitis and for psoriasis. It has also recently initiated a Phase 1 trial for PV-10 for liver cancer. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
Contact: Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO, COO
Porter, LeVay & Rose, Inc.
Marlon Nurse, VP – Investor Relations
Bill Gordon, SVP – Media Relations
Posted: November 2009